Redirecting to original paper in 30 seconds...

Click below to go immediately or wait for automatic redirect

arxiv_cv 95% Match Research Paper Urologists,Oncologists,Medical Imaging Researchers,AI Developers in Healthcare 5 days ago

ProstNFound+: A Prospective Study using Medical Foundation Models for Prostate Cancer Detection

computer-vision › medical-imaging
📄 Abstract

Abstract: Purpose: Medical foundation models (FMs) offer a path to build high-performance diagnostic systems. However, their application to prostate cancer (PCa) detection from micro-ultrasound ({\mu}US) remains untested in clinical settings. We present ProstNFound+, an adaptation of FMs for PCa detection from {\mu}US, along with its first prospective validation. Methods: ProstNFound+ incorporates a medical FM, adapter tuning, and a custom prompt encoder that embeds PCa-specific clinical biomarkers. The model generates a cancer heatmap and a risk score for clinically significant PCa. Following training on multi-center retrospective data, the model is prospectively evaluated on data acquired five years later from a new clinical site. Model predictions are benchmarked against standard clinical scoring protocols (PRI-MUS and PI-RADS). Results: ProstNFound+ shows strong generalization to the prospective data, with no performance degradation compared to retrospective evaluation. It aligns closely with clinical scores and produces interpretable heatmaps consistent with biopsy-confirmed lesions. Conclusion: The results highlight its potential for clinical deployment, offering a scalable and interpretable alternative to expert-driven protocols.
Authors (10)
Paul F. R. Wilson
Mohamed Harmanani
Minh Nguyen Nhat To
Amoon Jamzad
Tarek Elghareb
Zhuoxin Guo
+4 more
Submitted
October 30, 2025
arXiv Category
eess.IV
arXiv PDF

Key Contributions

ProstNFound+ adapts medical foundation models for prostate cancer detection using micro-ultrasound, incorporating a custom prompt encoder for clinical biomarkers. It demonstrates strong generalization in its first prospective clinical validation, showing no performance degradation compared to retrospective evaluation and benchmarking against standard clinical protocols.

Business Value

Offers a potentially more accurate and efficient method for prostate cancer detection, improving patient outcomes and potentially reducing healthcare costs associated with late-stage diagnosis or unnecessary biopsies.